Midazolam

CAS 59467-70-8 10 current records 2 historicalSmall Molecule

Who holds supplier records for Midazolam? 10 organisations hold a current record for Midazolam: an active US FDA Type II Drug Master File or a CEP. A further 2 organisations have only historical (inactive) DMF filings. 7 of them hold a valid EU Certificate of Suitability. Recorded organisation countries for current records: India (5), Italy (2), Israel (1) and China (1); not recorded for 1.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Midazolam: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/midazolam

Reading the evidence

  • 10 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • 8 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Midazolam expires 20 Jun 2038. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (10)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Midazolam. Country is the organisation's recorded country, not necessarily the manufacturing site.

India5Italy2Israel1China1Country not recorded for 1
Need Midazolam sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Valid CEP holder entries (7)

Certificates of Suitability on the EDQM register for Midazolam, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer. 8 certificates in total, including withdrawn, expired, suspended and repeat certificates.

HolderCountryCertificateIssuedEU GMP at holder's address
YICHANG HUMANWELL PHARMACEUTICAL CO., LTD. YichangCN
CEP 2023-434 - Rev 01
Midazolam
Jul 2026Inspected Jul 2026
Hungary
WAVELENGTH ENTERPRISES LTD. Petah TikvaIL
CEP 2006-267 - Rev 09
Midazolam
Feb 2026—
COHANCE LIFESCIENCES LIMITED MumbaiIN
CEP 2010-141 - Rev 03
Midazolam
Dec 2025—
LAKE CHEMICALS PRIVATE LIMITED Shivaji NagarIN
R1-CEP 2016-316 - Rev 00
Midazolam
Feb 2023—
F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. Montecchio MaggioreIT
R1-CEP 2012-383 - Rev 01
Midazolam
Oct 2022—
SUN PHARMACEUTICAL INDUSTRIES LIMITED MumbaiIN
R1-CEP 2002-059 - Rev 05
Midazolam
Sept 2021—
Cambrex Profarmaco Milano S.r.l. PaulloIT
R1-CEP 2006-025 - Rev 03
Midazolam
Jul 2017—

The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.

Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.

Historical records (2)

Organisations whose Type II DMFs for Midazolam are no longer active. These show a past filing, not current supply.

Show all 2 historical records
  • DIOSYNTH BV
    Inactive DMF 12910 · filed Mar 1998
  • ABBOTT LABORATORIES HOSP PRODUCTS DIV
    Inactive DMF 12745 · filed Nov 1997

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (40 listed products contain Midazolam). The latest listed patent expires 20 Jun 2038. The latest listed exclusivity ended 17 May 2026. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Other forms of this substance

A DMF or CEP is listed under the form it names. Salts, esters and hydrates of the same active substance have their own records:

Overview

Midazolam is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL655).

Chemical identity

IUPAC name
8-chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine
Canonical SMILES
CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F
InChIKey
DDLIGBOFAVUZHB-UHFFFAOYSA-N
Synonyms
Midazolam, Midazolam civ, Midazolam in 0.8% sodium chloride, Midazolam in 0.9% sodium chloride, Nayzilam, USL-261, USL261, Buccolam, Midazolamum, mezolam, CHEBI:6931, Epistatus

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Benzodiazepine
Chemical structure
Benzodiazepines

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Midazolam?

10 organisations hold an active US FDA Type II Drug Master File or a CEP for Midazolam: CAMBREX PROFARMACO MILANO SRL (Italy), COHANCE LIFESCIENCES LTD (India), WAVELENGTH ENTERPRISES LTD (Israel), GLOBAL CALCIUM PRIVATE LTD (India), SOLARA ACTIVE PHARMA SCIENCES LTD (India), SUPRIYA LIFESCIENCE LTD (India), FIS FABBRICA ITALIANA SINTETICI SPA (Italy) and LAKE CHEMICALS PRIVATE LTD, and 2 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Midazolam Drug Master Files are active?

CAMBREX PROFARMACO MILANO SRL (DMF 12686, 37102), COHANCE LIFESCIENCES LTD (DMF 26871), WAVELENGTH ENTERPRISES LTD (DMF 12553), GLOBAL CALCIUM PRIVATE LTD (DMF 39365), SOLARA ACTIVE PHARMA SCIENCES LTD (DMF 29881) and SUPRIYA LIFESCIENCE LTD (DMF 43271). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Midazolam records mean?

2 organisations have only inactive Type II DMFs for Midazolam. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

Does Midazolam have a European Certificate of Suitability?

Yes. 7 organisations hold a valid CEP for Midazolam on the EDQM register, including YICHANG HUMANWELL PHARMACEUTICAL CO., LTD. Yichang (CN), WAVELENGTH ENTERPRISES LTD. Petah Tikva (IL), COHANCE LIFESCIENCES LIMITED Mumbai (IN), LAKE CHEMICALS PRIVATE LIMITED Shivaji Nagar (IN), F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. Montecchio Maggiore (IT) and SUN PHARMACEUTICAL INDUSTRIES LIMITED Mumbai (IN) and 1 more. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

Does the FDA Orange Book list patents for products containing Midazolam?

Yes. The latest patent listed for an approved US product containing Midazolam expires 20 Jun 2038, across 40 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Midazolam supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Midazolam?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.